Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1993 2
1994 1
1995 1
1996 2
1998 1
2000 1
2001 1
2002 3
2003 5
2004 8
2005 5
2006 4
2007 3
2008 5
2009 3
2010 4
2011 1
2015 2
2016 2
2017 3
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

58 results
Results by year
Filters applied: . Clear all
Page 1
Efficacy of a Cell-Culture-Derived Quadrivalent Influenza Vaccine in Children.
Nolan T, Fortanier AC, Leav B, Põder A, Bravo LC, Szymański HT, Heeringa M, Vermeulen W, Matassa V, Smolenov I, Edelman JM. Nolan T, et al. Among authors: edelman jm. N Engl J Med. 2021 Oct 14;385(16):1485-1495. doi: 10.1056/NEJMoa2024848. N Engl J Med. 2021. PMID: 34644472 Clinical Trial.
Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial.
Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, Stoel BC, Huang L, Yao Z, Edelman JM, McElvaney NG; RAPID Trial Study Group. Chapman KR, et al. Among authors: edelman jm. Lancet. 2015 Jul 25;386(9991):360-8. doi: 10.1016/S0140-6736(15)60860-1. Epub 2015 May 27. Lancet. 2015. PMID: 26026936 Clinical Trial.
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial.
Merkies ISJ, Lawo JP, Edelman JM, De Bleecker JL, Sommer C, Robberecht W, Saarela M, Kamienowski J, Stelmasiak Z, Mielke O, Tackenberg B, Léger JM; PRIMA trial investigators. Merkies ISJ, et al. Among authors: edelman jm. J Peripher Nerv Syst. 2017 Jun;22(2):149-152. doi: 10.1111/jns.12204. J Peripher Nerv Syst. 2017. PMID: 28594116 Free PMC article. Clinical Trial. No abstract available.
Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases.
Wanner A, Groft SC, Teagarden JR, Krischer J, Davis BR, Coffey CS, Hickam DH, Teckman J, Nelson DR, McCaleb ML, Loomba R, Strange C, Sandhaus RA, Brantly M, Edelman JM, Farrugia A. Wanner A, et al. Among authors: edelman jm. Chronic Obstr Pulm Dis. 2015 Apr 28;2(2):177-190. doi: 10.15326/jcopdf.2.2.2015.0132. Chronic Obstr Pulm Dis. 2015. PMID: 28848840 Free PMC article.
ADVANTAGE: Merck does say "no".
Edelman JM. Edelman JM. Ann Intern Med. 2008 Nov 18;149(10):774-5; author reply 775. doi: 10.7326/0003-4819-149-10-200811180-00027. Ann Intern Med. 2008. PMID: 19017607 No abstract available.
ADVANTAGE: science first, marketing second.
Edelman JM. Edelman JM. Ann Intern Med. 2008 Nov 18;149(10):773; author reply 773-4. doi: 10.7326/0003-4819-149-10-200811180-00024. Ann Intern Med. 2008. PMID: 19017606 No abstract available.
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE).
McElvaney NG, Burdon J, Holmes M, Glanville A, Wark PA, Thompson PJ, Hernandez P, Chlumsky J, Teschler H, Ficker JH, Seersholm N, Altraja A, Mäkitaro R, Chorostowska-Wynimko J, Sanak M, Stoicescu PI, Piitulainen E, Vit O, Wencker M, Tortorici MA, Fries M, Edelman JM, Chapman KR; RAPID Extension Trial Group. McElvaney NG, et al. Among authors: edelman jm. Lancet Respir Med. 2017 Jan;5(1):51-60. doi: 10.1016/S2213-2600(16)30430-1. Epub 2016 Dec 2. Lancet Respir Med. 2017. PMID: 27916480 Clinical Trial.
Quantitative disease progression model of α-1 proteinase inhibitor therapy on computed tomography lung density in patients with α-1 antitrypsin deficiency.
Tortorici MA, Rogers JA, Vit O, Bexon M, Sandhaus RA, Burdon J, Chorostowska-Wynimko J, Thompson P, Stocks J, McElvaney NG, Chapman KR, Edelman JM. Tortorici MA, et al. Among authors: edelman jm. Br J Clin Pharmacol. 2017 Nov;83(11):2386-2397. doi: 10.1111/bcp.13358. Epub 2017 Aug 11. Br J Clin Pharmacol. 2017. PMID: 28662542 Free PMC article.
58 results